Sirolimus
Information
- Drug Name
- Sirolimus
- Description
- Entry(CIViC)
- 15
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| skin squamous cell carcinoma |
EGFR p.Pro753Ser (p.P753S) ( ENST00000450046.2, ENST00000275493.7, ENST00000455089.5 ) EGFR p.Pro753Ser (p.P753S) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24934779 | Detail |
| endometrial adenocarcinoma |
MTOR p.Ser2215Tyr (p.S2215Y) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Ser2215Tyr (p.S2215Y) ( ENST00000361445.9, ENST00000703140.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24631838 | Detail |
| T-cell acute lymphoblastic leukemia |
MTOR p.Cys1483Tyr (p.C1483Y) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Cys1483Tyr (p.C1483Y) ( ENST00000361445.9, ENST00000703140.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24631838 | Detail |
| clear cell renal cell carcinoma |
MTOR p.Glu1799Lys (p.E1799K) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Glu1799Lys (p.E1799K) ( ENST00000361445.9, ENST00000703140.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24631838 | Detail |
| skin melanoma | NF1 MUTATION NF1 MUTATION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 23171796 | Detail |
| lung non-small cell carcinoma |
TSC1 FRAMESHIFT TRUNCATION ( ENST00000298552.9 ) TSC1 FRAMESHIFT TRUNCATION ( ENST00000298552.9 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 19966866 | Detail |
| breast cancer |
MTOR p.Phe2108Leu (p.F2108L) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Phe2108Leu (p.F2108L) ( ENST00000361445.9, ENST00000703140.1 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 27279227 | Detail |
| breast cancer |
MTOR p.Met2327Ile (p.M2327I) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Met2327Ile (p.M2327I) ( ENST00000703140.1, ENST00000361445.9 ) |
D |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 27279227 | Detail |
| breast cancer |
MTOR p.Ala2034Val (p.A2034V) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Ala2034Val (p.A2034V) ( ENST00000361445.9, ENST00000703140.1 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 27279227 | Detail |
| Peutz-Jeghers syndrome |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 1 | 18281551 | Detail |
| Peutz-Jeghers syndrome |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 1 | 19541609 | Detail |
| lung non-small cell carcinoma |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 26027660 | Detail |
| cancer | FBXW7 LOSS-OF-FUNCTION FBXW7 LOSS-OF-FUNCTION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 18787170 | Detail |
| breast cancer |
PIK3CA p.Glu542Lys (p.E542K) ( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K) ( ENST00000263967.4, ENST00000643187.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 15647370 | Detail |
| lung non-small cell carcinoma |
ERBB2 p.Tyr772_Ala775dup (p.Y772_A775dup) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Tyr772_Ala775dup (p.Y772_A775dup) ( ENST00000541774.5, ENST00000269571.10, ENST00000445658.6, ENST00000406381.6, ENST00000584450.5, ENST00000584601.5 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 19122144 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| 72-year old male patient presents with SCC with a ... | EGFR |
EGFR p.Pro753Ser (p.P753S) ( ENST00000450046.2, ENST00000275493.7, ENST00000455089.5 ) EGFR p.Pro753Ser (p.P753S) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Cell lines with various putative activating mutati... | MTOR |
MTOR p.Ser2215Tyr (p.S2215Y) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Ser2215Tyr (p.S2215Y) ( ENST00000361445.9, ENST00000703140.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Cell lines with various putative activating mutati... | MTOR |
MTOR p.Cys1483Tyr (p.C1483Y) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Cys1483Tyr (p.C1483Y) ( ENST00000361445.9, ENST00000703140.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Cell lines with various putative activating mutati... | MTOR |
MTOR p.Glu1799Lys (p.E1799K) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Glu1799Lys (p.E1799K) ( ENST00000361445.9, ENST00000703140.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study of mouse melanoma both in-vitro ... | NF1 | NF1 MUTATION NF1 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Following rapamycin treatment of mice with KrasG12... | TSC1 |
TSC1 FRAMESHIFT TRUNCATION ( ENST00000298552.9 ) TSC1 FRAMESHIFT TRUNCATION ( ENST00000298552.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| MCF-7 breast cancer cell line was exposed to mTOR ... | MTOR |
MTOR p.Phe2108Leu (p.F2108L) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Phe2108Leu (p.F2108L) ( ENST00000361445.9, ENST00000703140.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| MCF-7 breast cancer cell line was exposed to mTOR ... | MTOR |
MTOR p.Met2327Ile (p.M2327I) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Met2327Ile (p.M2327I) ( ENST00000703140.1, ENST00000361445.9 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| MCF-7 breast cancer cell line was exposed to mTOR ... | MTOR |
MTOR p.Ala2034Val (p.A2034V) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Ala2034Val (p.A2034V) ( ENST00000361445.9, ENST00000703140.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Preclinical study in a mouse model of Peutz-Jegher... | STK11 |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
Sensitivity | true | CIViC Evidence | detail |
| Treatment of mice with a heterozygous loss of Lkb1... | STK11 |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 5 NSCLC cell lines. Two LKB1 ... | STK11 |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
Sensitivity | false | CIViC Evidence | detail |
| FBXW7 was shown to target mTOR for ubiquitination ... | FBXW7 | FBXW7 LOSS-OF-FUNCTION FBXW7 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| Rapamycin inhibits transformation induced by mutat... | PIK3CA |
PIK3CA p.Glu542Lys (p.E542K) ( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K) ( ENST00000263967.4, ENST00000643187.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| In preclinical studies of transgenic mice and xeno... | ERBB2 |
ERBB2 p.Tyr772_Ala775dup (p.Y772_A775dup) ( ENST00000269571.10, ENST00000406381.6, ENST00000445658.6, ENST00000541774.5, ENST00000584450.5, ENST00000584601.5 ) ERBB2 p.Tyr772_Ala775dup (p.Y772_A775dup) ( ENST00000541774.5, ENST00000269571.10, ENST00000445658.6, ENST00000406381.6, ENST00000584450.5, ENST00000584601.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03192397 | Active, not recruiting | Phase 1/Phase 2 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | August 9, 2017 | May 21, 2027 |
| NCT03217669 | Active, not recruiting | Phase 1 | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | February 22, 2018 | August 1, 2025 |
| NCT04473911 | Active, not recruiting | Phase 1 | Haplo Peripheral Blood Sct In GVHD Prevention | August 14, 2020 | October 2024 |
| NCT01869114 | Active, not recruiting | Phase 2 | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | July 8, 2013 | April 19, 2028 |
| NCT00061568 | Active, not recruiting | Phase 1/Phase 2 | Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias | July 16, 2004 | January 31, 2026 |
| NCT02629120 | Active, not recruiting | Phase 1/Phase 2 | High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease | December 17, 2015 | November 30, 2026 |
| NCT03077542 | Active, not recruiting | Phase 1/Phase 2 | Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease | April 6, 2017 | August 31, 2026 |
| NCT04411654 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) | June 29, 2021 | May 2028 |
| NCT01428973 | Active, not recruiting | Phase 2 | Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens | September 2011 | December 2024 |
| NCT01163357 | Active, not recruiting | Phase 1 | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | January 28, 2011 | December 31, 2024 |
| NCT04339062 | Active, not recruiting | Phase 1/Phase 2 | Cemiplimab in AlloSCT/SOT Recipients With CSCC | November 3, 2020 | January 1, 2025 |
| NCT02584647 | Active, not recruiting | Phase 1/Phase 2 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors | November 4, 2015 | June 2024 |
| NCT00092222 | Active, not recruiting | Phase 2 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | October 28, 2004 | October 1, 2025 |
| NCT03504241 | Active, not recruiting | Phase 1 | Tolerance by Engaging Antigen During Cellular Homeostasis | July 30, 2018 | December 2029 |
| NCT01885689 | Active, not recruiting | Phase 2 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | February 10, 2014 | December 30, 2024 |
| NCT04094675 | Active, not recruiting | Phase 2 | Sirolimus for Cowden Syndrome With Colon Polyposis | September 16, 2019 | February 2025 |
| NCT03456700 | Active, not recruiting | Phase 2 | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | March 30, 2018 | June 30, 2024 |
| NCT00544115 | Active, not recruiting | Phase 2 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | October 16, 2001 | December 30, 2024 |
| NCT01850108 | Active, not recruiting | N/A | Non-Myeloablative Conditioning and Bone Marrow Transplantation | May 2013 | December 31, 2024 |
| NCT00977691 | Active, not recruiting | Phase 1/Phase 2 | Haploidentical PBMC Transplant for Severe Congenital Anemias | December 14, 2009 | September 10, 2026 |
| NCT04339101 | Active, not recruiting | Phase 2 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | November 11, 2020 | May 22, 2024 |
| NCT03225417 | Active, not recruiting | Phase 1/Phase 2 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | May 16, 2017 | December 31, 2024 |
| NCT02722668 | Active, not recruiting | Phase 2 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | May 15, 2017 | December 2029 |
| NCT00792948 | Active, not recruiting | Phase 2 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | September 1, 2009 | January 6, 2025 |
| NCT01087554 | Active, not recruiting | Phase 1 | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | March 2010 | August 18, 2026 |
| NCT00195195 | Completed | Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries | January 2005 | June 2008 | |
| NCT00195273 | Completed | Phase 3 | Study Evaluating Sirolimus in Kidney Transplant Recipients | November 2004 | July 2008 |
| NCT00195429 | Completed | Phase 4 | A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients | August 2005 | October 2007 |
| NCT00223054 | Completed | Polymorphism of the Cytochrome P450-system in Renal Transplants | March 2005 | October 2006 | |
| NCT00240994 | Completed | Phase 2 | Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients | January 2005 | November 2009 |
| NCT00254709 | Completed | Phase 4 | Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients | October 2002 | September 2005 |
| NCT00261820 | Completed | Phase 4 | Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients | January 2005 | |
| NCT00266123 | Completed | Phase 4 | Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients | March 2004 | July 2007 |
| NCT00275522 | Completed | Phase 4 | The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients. | December 2005 | December 2007 |
| NCT00275535 | Completed | Phase 4 | The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients | April 2001 | December 2008 |
| NCT00282217 | Completed | Phase 4 | Study Evaluating Sirolimus in the Treatment of Kidney Transplant | August 2006 | |
| NCT00282282 | Completed | Phase 2 | Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation | January 2006 | July 2009 |
| NCT00305396 | Completed | Phase 4 | Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation | April 2004 | March 2005 |
| NCT00305682 | Completed | Phase 2 | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | June 2005 | December 12, 2019 |
| NCT05345119 | Completed | Sirolimus in Graves' Orbitopathy | January 15, 2020 | June 15, 2021 | |
| NCT00317785 | Completed | Phase 2 | Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases | May 2005 | |
| NCT00317798 | Completed | Phase 1 | Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma | April 2006 | April 2011 |
| NCT04775173 | Completed | Phase 2 | Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. | February 17, 2021 | August 10, 2023 |
| NCT00321906 | Completed | Phase 4 | Comparison of Sirolimus and Azathioprine in Lung Transplantation | April 2002 | August 2011 |
| NCT00328770 | Completed | Phase 2/Phase 3 | De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma | December 1996 | March 2006 |
| NCT00346918 | Completed | Phase 3 | Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | June 2006 | June 2010 |
| NCT00350181 | Completed | Phase 2 | Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | August 2006 | April 2010 |
| NCT00352092 | Completed | Phase 4 | Pilot Study for HLA Identical Living Donor Renal Transplant Recipients | June 2002 | December 2007 |
| NCT00352976 | Completed | Phase 2/Phase 3 | TBI Dose De-escalation for Fanconi Anemia | May 18, 2006 | October 9, 2020 |
| NCT00353301 | Completed | Phase 2 | Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | July 2006 | March 2012 |
| NCT00355862 | Completed | Phase 3 | Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma | January 2006 | May 2014 |
| NCT04707209 | Completed | N/A | Sirolimus for Retinal Astrocytic Hamartoma | November 4, 2020 | March 22, 2024 |
| NCT00368914 | Completed | Phase 1 | Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors | December 2004 | June 2009 |
| NCT00369382 | Completed | Phase 4 | Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients | September 2006 | May 2010 |
| NCT00374647 | Completed | Phase 4 | Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts | March 2005 | December 2007 |
| NCT00382109 | Completed | Phase 3 | Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | March 2007 | June 30, 2017 |
| NCT00388362 | Completed | Phase 2 | Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease | November 2005 | August 2012 |
| NCT00392951 | Completed | Phase 1/Phase 2 | Sirolimus for Autoimmune Disease of Blood Cells | December 2006 | February 2016 |
| NCT00406393 | Completed | Phase 3 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | November 2006 | October 2015 |
| NCT00414648 | Completed | Phase 3 | Efficacy and Safety of Sirolimus in LAM | December 2006 | February 2011 |
| NCT00428064 | Completed | Phase 3 | Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients | May 1998 | June 2004 |
| NCT00433485 | Completed | Phase 1 | Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants | March 2008 | |
| NCT00434811 | Completed | Phase 3 | Islet Transplantation in Type 1 Diabetes | October 2006 | May 2014 |
| NCT00434850 | Completed | Phase 2 | Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes | October 2006 | November 2013 |
| NCT00450320 | Completed | Phase 1 | Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma | October 2007 | September 2009 |
| NCT00455013 | Completed | Phase 2 | A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation | July 2007 | August 2012 |
| NCT00464555 | Completed | Phase 2 | Strategies to Improve Islet Survival | December 2006 | February 2014 |
| NCT00484094 | Completed | Study Investigating Rapamune For Post-Marketing Surveillance | July 2011 | June 2015 | |
| NCT04470804 | Completed | Phase 4 | Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA | July 1, 2020 | July 31, 2022 |
| NCT04448873 | Completed | Phase 4 | Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma | July 1, 2020 | July 1, 2023 |
| NCT00491517 | Completed | Phase 2 | Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety | March 2007 | August 2009 |
| NCT00499486 | Completed | Phase 2 | Sirolimus in Treating Patients With Advanced Pancreatic Cancer | January 2005 | June 2009 |
| NCT00507793 | Completed | Phase 4 | Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus | April 2000 | June 2002 |
| NCT00509613 | Completed | Phase 1 | Phase 1 Study With Sorafenib and Sirolimus | June 2007 | |
| NCT00513474 | Completed | Phase 1 | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | January 2008 | February 12, 2013 |
| NCT04341675 | Completed | Phase 2 | Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia | April 24, 2020 | September 15, 2020 |
| NCT00555373 | Completed | N/A | Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression | November 2007 | November 2012 |
| NCT00556933 | Completed | Phase 4 | Improved Induction and Maintenance Immunosuppression in Kidney Transplantation | April 1, 2004 | June 1, 2011 |
| NCT00565773 | Completed | Phase 2 | Belatacept Post Depletional Repopulation to Facilitate Tolerance | December 2007 | July 1, 2017 |
| NCT00577278 | Completed | Phase 2 | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | October 3, 2007 | December 14, 2023 |
| NCT00589563 | Completed | Phase 2 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | May 2007 | February 2012 |
| NCT00602693 | Completed | Phase 1 | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | July 23, 2007 | April 16, 2015 |
| NCT00612274 | Completed | Early Phase 1 | Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation | October 2007 | October 2014 |
| NCT00634244 | Completed | Phase 2 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | October 2008 | October 2014 |
| NCT00634270 | Completed | Phase 2 | A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas | April 2008 | December 2015 |
| NCT00656643 | Completed | Phase 2 | Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema | June 2008 | May 2012 |
| NCT00670423 | Completed | Phase 1 | A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation | May 16, 2008 | October 16, 2013 |
| NCT04161144 | Completed | Phase 2 | Enhancing Self Regulation Among Smokers | October 1, 2018 | December 20, 2019 |
| NCT00697112 | Completed | Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD) | May 2008 | December 2012 | |
| NCT00711490 | Completed | Phase 1/Phase 2 | Sirolimus to Treat Diabetic Macular Edema | July 2008 | January 2011 |
| NCT00713284 | Completed | Phase 4 | Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic | May 2007 | November 2010 |
| NCT00766649 | Completed | Phase 1/Phase 2 | Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD | October 2008 | July 2012 |
| NCT00768729 | Completed | Phase 1 | Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation | May 2009 | December 2012 |
| NCT03765944 | Completed | Phase 1 | Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets | December 5, 2018 | December 29, 2018 |
| NCT00811915 | Completed | Phase 3 | Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation | January 2009 | June 2014 |
| NCT00812123 | Completed | Phase 4 | Calcineurin Free Immunosuppression in Renal Transplant Recipients | January 2001 | July 2005 |
| NCT00814944 | Completed | Phase 2 | A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model | April 2009 | October 2009 |
| NCT00821080 | Completed | Phase 1 | Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | October 2008 | February 2015 |
| NCT00859183 | Completed | Phase 4 | Oral Sirolimus for In-Stent Restenosis | October 2001 | March 2004 |
| NCT03605927 | Completed | Phase 1 | CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease | February 15, 2019 | September 1, 2023 |
| NCT00866879 | Completed | Phase 4 | Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients | June 2007 | March 2019 |
| NCT00876434 | Completed | Phase 1 | Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti | April 1, 2009 | February 10, 2011 |
| NCT00890500 | Completed | Phase 1 | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | January 2011 | October 2013 |
| NCT00895583 | Completed | Phase 4 | Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients | June 2009 | August 2013 |
| NCT03583307 | Completed | N/A | Efficacy and Safety of Sirolimus to Vascular Anomalies | June 1, 2018 | February 19, 2021 |
| NCT00923845 | Completed | Phase 2 | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | March 1, 2008 | June 22, 2017 |
| NCT00928018 | Completed | Phase 3 | Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma | June 2009 | November 2014 |
| NCT03468478 | Completed | Phase 4 | Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation | June 18, 2017 | August 23, 2021 |
| NCT00940381 | Completed | Phase 1 | Sirolimus and Cetuximab in Advanced Malignancies | July 2009 | May 2014 |
| NCT00971789 | Completed | Phase 2 | Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes | July 2008 | October 2012 |
| NCT03433183 | Completed | Phase 2 | SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | October 2, 2019 | October 1, 2023 |
| NCT03364764 | Completed | Phase 4 | Sirolimus Treatment for Refractory PRCA | February 1, 2018 | May 1, 2021 |
| NCT01027000 | Completed | Phase 2 | Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 2010 | April 2023 |
| NCT03253913 | Completed | Phase 2 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial | March 31, 2018 | October 15, 2022 |
| NCT02296762 | Completed | Phase 1 | Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition | February 2010 | February 2010 |
| NCT02443818 | Completed | Phase 2 | Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA | May 2015 | November 2016 |
| NCT02423915 | Completed | Phase 1 | Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | July 30, 2015 | October 6, 2020 |
| NCT02428296 | Completed | Phase 2 | Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation | April 23, 2015 | February 14, 2018 |
| NCT02440789 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) | December 21, 2015 | February 1, 2018 |
| NCT00038948 | Completed | Phase 3 | Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients | January 2002 | May 2008 |
| NCT00040508 | Completed | Phase 2 | Sirolimus for Focal Segmental Glomerulosclerosis | June 2002 | January 2005 |
| NCT00043979 | Completed | Phase 2 | Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | September 19, 2002 | December 14, 2011 |
| NCT00050713 | Completed | Phase 2 | Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy | December 17, 2002 | August 27, 2007 |
| NCT00076570 | Completed | Phase 2 | Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation | January 2004 | August 2012 |
| NCT00078559 | Completed | Phase 1/Phase 2 | Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults | November 2003 | February 2010 |
| NCT00079183 | Completed | Phase 2 | Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment | April 2002 | June 10, 2010 |
| NCT00089037 | Completed | Phase 1/Phase 2 | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | June 2003 | April 2005 |
| NCT00105001 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | November 2004 | May 8, 2015 |
| NCT00118742 | Completed | Phase 4 | Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant | August 2005 | December 2008 |
| NCT00121810 | Completed | Phase 4 | Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients | August 2003 | November 2009 |
| NCT00129961 | Completed | Phase 4 | Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients | August 2005 | January 2009 |
| NCT00133367 | Completed | Phase 2 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | August 2005 | November 2011 |
| NCT00144677 | Completed | Phase 2 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | November 2003 | June 2006 |
| NCT00144703 | Completed | Phase 2 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | July 2002 | November 2006 |
| NCT00146614 | Completed | Phase 2 | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation | July 2002 | April 2003 |
| NCT00170053 | Completed | Phase 1 | Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids | June 2005 | September 2008 |
| NCT00183248 | Completed | Phase 1/Phase 2 | Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients | September 2004 | November 2009 |
| NCT00188955 | Completed | Phase 4 | Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant | March 2004 | October 2008 |
| NCT00189202 | Completed | Phase 2/Phase 3 | Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans | August 2004 | July 1, 2008 |
| NCT02686619 | Completed | Phase 3 | Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients | November 2004 | January 2011 |
| NCT00014911 | Completed | Phase 2 | Islet Transplantation for Type 1 Diabetes | April 2001 | August 2010 |
| NCT02683291 | Completed | Phase 4 | Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients | January 2014 | January 2016 |
| NCT02062944 | Completed | N/A | SRL (Sirolimus) Withdrawal | March 2013 | July 2020 |
| NCT00023231 | Completed | N/A | Pediatric Kidney Transplant Without Calcineurin Inhibitors | February 2001 | August 2006 |
| NCT02588339 | Completed | Phase 2 | Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention | March 4, 2016 | July 13, 2021 |
| NCT02117596 | Completed | N/A | Calcineurin Inhibitor Based Immunosuppression Withdrawal | November 2007 | November 2012 |
| NCT02583893 | Completed | Phase 2 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | October 7, 2015 | May 17, 2023 |
| NCT02145559 | Completed | Phase 1 | A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors | April 2014 | July 2018 |
| NCT02513303 | Completed | Phase 3 | Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes | November 2015 | June 2021 |
| NCT02509468 | Completed | Phase 2 | suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS | September 30, 2015 | March 2019 |
| NCT02487485 | Completed | Phase 2 | Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects | March 2016 | January 2020 |
| NCT02449564 | Completed | N/A | The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors | November 24, 2014 | November 3, 2017 |
| NCT02296749 | Completed | Phase 1 | Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition | January 2010 | February 2010 |
| NCT02357342 | Completed | Phase 2 | Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD | April 2015 | January 2017 |
| NCT01087983 | Completed | Phase 1 | Lapatinib With Sirolimus or Metformin | March 2010 | September 2015 |
| NCT01120028 | Completed | Phase 2/Phase 3 | Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy | September 2010 | March 2020 |
| NCT01181271 | Completed | Phase 2 | Tandem Auto-Allo Transplant for Lymphoma | August 2010 | February 2016 |
| NCT01184885 | Completed | Early Phase 1 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | July 2010 | April 2013 |
| NCT01184898 | Completed | N/A | Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | July 2010 | February 2016 |
| NCT01195922 | Completed | Phase 1/Phase 2 | Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma | August 2010 | December 2015 |
| NCT01217125 | Completed | Phase 4 | Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis | October 2008 | May 2011 |
| NCT03188068 | Completed | Phase 2 | Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma | June 1, 2017 | December 31, 2021 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01236378 | Completed | Phase 1 | Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients | December 2010 | April 2011 |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT01265030 | Completed | Phase 1/Phase 2 | A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis | February 2014 | December 22, 2021 |
| NCT01266057 | Completed | Phase 1 | Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | April 28, 2011 | February 11, 2021 |
| NCT03095703 | Completed | Phase 2 | Sirolimus and Familial Adenomatous Polyposis (FAP) | October 3, 2017 | December 10, 2018 |
| NCT03072485 | Completed | Phase 1 | Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers | March 1, 2017 | February 22, 2019 |
| NCT01331135 | Completed | Phase 1 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | April 2011 | August 9, 2017 |
| NCT01363752 | Completed | Phase 4 | A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. | March 8, 2011 | September 18, 2013 |
| NCT01374750 | Completed | Phase 2 | Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC) | May 2010 | May 2016 |
| NCT01379209 | Completed | Phase 1/Phase 2 | Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | September 2011 | April 2017 |
| NCT03047980 | Completed | Phase 2/Phase 3 | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | January 2017 | October 27, 2020 |
| NCT01445548 | Completed | Phase 1/Phase 2 | Sirolimus for Advanced Age-Related Macular Degeneration | September 2011 | February 2014 |
| NCT02917096 | Completed | Phase 1 | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis | November 13, 2016 | August 31, 2023 |
| NCT01462006 | Completed | N/A | Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF) | October 2011 | March 2016 |
| NCT02891603 | Completed | Phase 1/Phase 2 | A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression | June 8, 2017 | April 18, 2022 |
| NCT02867800 | Completed | Phase 1 | Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease | July 2016 | December 30, 2023 |
| NCT00006178 | Completed | Phase 2 | Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection | August 2000 | December 2007 |
| NCT01517074 | Completed | Phase 1/Phase 2 | Sirolimus Injections for Autoimmune Scleritis | January 2012 | April 2014 |
| NCT01522820 | Completed | Phase 1 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | March 2012 | July 2016 |
| NCT02821026 | Completed | Phase 1/Phase 2 | Omental Islet Transplant | May 2016 | November 13, 2019 |
| NCT01536054 | Completed | Phase 1 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | August 20, 2012 | April 21, 2015 |
| NCT01537107 | Completed | Phase 1 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | March 5, 2012 | June 27, 2018 |
| NCT02806947 | Completed | Phase 2 | A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501) | October 2016 | February 19, 2019 |
| NCT01595841 | Completed | Phase 2 | Sirolimus Use in Angioplasty for Vascular Access Extension | December 2011 | March 2022 |
| NCT01625351 | Completed | Phase 1 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | August 20, 2012 | February 10, 2020 |
| NCT01632605 | Completed | N/A | The Vienna RAP Pilot Study | November 2009 | April 2012 |
| NCT01649609 | Completed | N/A | Using mTOR Inhibitors in the Prevention of BK Nephropathy | March 2012 | December 2016 |
| NCT02793544 | Completed | Phase 2 | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | December 2016 | March 2020 |
| NCT02766465 | Completed | Phase 2 | Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) | November 2016 | May 2, 2023 |
| NCT02756572 | Completed | Phase 2 | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | September 22, 2016 | July 1, 2020 |
| NCT01689987 | Completed | Phase 1 | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | September 2012 | |
| NCT02753309 | Completed | Early Phase 1 | A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer | June 2016 | March 2, 2021 |
| NCT01713400 | Completed | Phase 2 | Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease | February 25, 2013 | June 14, 2018 |
| NCT01737502 | Completed | Phase 1/Phase 2 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | May 14, 2014 | April 24, 2023 |
| NCT01754389 | Completed | Phase 2 | Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant | January 2013 | November 2016 |
| NCT02732899 | Completed | Phase 2 | Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD | April 2016 | April 4, 2017 |
| NCT01791088 | Completed | Phase 1 | Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | June 13, 2012 | August 17, 2018 |
| NCT01809860 | Completed | Phase 1 | A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects | November 2011 | January 2012 |
| NCT01811667 | Completed | Phase 3 | Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations | May 2012 | January 2016 |
| NCT02711202 | Completed | N/A | Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation | January 2007 | March 2009 |
| NCT01822015 | Completed | Early Phase 1 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 15, 2013 | December 12, 2019 |
| NCT01888302 | Completed | Phase 1 | Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery | September 2013 | June 2016 |
| NCT01927120 | Completed | Phase 2 | In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis | March 25, 2014 | March 9, 2017 |
| NCT01929642 | Completed | Phase 2 | Rapalogues for Autism Phenotype in TSC: A Feasibility Study | July 2013 | August 2016 |
| NCT01938573 | Completed | Phase 1/Phase 2 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | October 2013 | August 18, 2016 |
| NCT02688881 | Completed | Phase 4 | Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors | February 5, 2017 | February 24, 2021 |
| NCT01976390 | Completed | N/A | Comparing Everolimus and Sirolimus in Renal Transplant Recipients | October 1, 2013 | August 31, 2019 |
| NCT02008877 | Completed | Phase 1/Phase 2 | SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | December 2013 | July 2018 |
| NCT04370795 | Enrolling by invitation | Phase 1/Phase 2 | Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus | June 23, 2024 | September 9, 2026 |
| NCT03292861 | Enrolling by invitation | Phase 2 | The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients | September 13, 2018 | October 31, 2025 |
| NCT06022068 | Enrolling by invitation | Phase 1/Phase 2 | Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography | September 1, 2023 | January 31, 2025 |
| NCT01309022 | No longer available | Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) | |||
| NCT01049633 | No longer available | B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure | |||
| NCT05746689 | Not yet recruiting | N/A | Study of Sirolimus in IgG4-related Disease | March 1, 2023 | December 31, 2028 |
| NCT05458492 | Not yet recruiting | Phase 2 | Sirolimus in Cutaneous Sarcoidosis | July 2022 | May 2027 |
| NCT06287944 | Not yet recruiting | Phase 1 | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | June 18, 2024 | February 24, 2027 |
| NCT04736953 | Not yet recruiting | Phase 2 | Sirolimus Treatment Of Patients With SLE | January 1, 2025 | January 1, 2029 |
| NCT06279494 | Not yet recruiting | Phase 1/Phase 2 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | March 2024 | March 2025 |
| NCT06080165 | Not yet recruiting | Phase 1/Phase 2 | Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations | July 2024 | June 2028 |
| NCT06084780 | Not yet recruiting | Phase 2 | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) | October 2024 | December 31, 2025 |
| NCT04598815 | Not yet recruiting | Phase 2 | Sirolimus for Graves' Orbitopathy (GO) | June 1, 2023 | May 31, 2025 |
| NCT06091332 | Not yet recruiting | Phase 2 | Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: a Single Centre, Randomised, Placebo-controlled Trial | December 1, 2023 | December 31, 2025 |
| NCT06261060 | Not yet recruiting | Phase 2 | Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder | August 31, 2024 | June 11, 2028 |
| NCT06358638 | Recruiting | Phase 2 | Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY | April 2024 | September 2054 |
| NCT01203722 | Recruiting | Phase 1/Phase 2 | Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | September 2010 | December 2025 |
| NCT01499888 | Recruiting | Phase 1/Phase 2 | Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) | November 11, 2011 | May 2025 |
| NCT02042326 | Recruiting | Phase 2 | Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | September 12, 2014 | September 2024 |
| NCT02105766 | Recruiting | Phase 2 | Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure | April 21, 2014 | December 31, 2024 |
| NCT02432560 | Recruiting | Safety and Durability of Sirolimus for Treatment of LAM | March 2015 | July 31, 2025 | |
| NCT02574728 | Recruiting | Phase 2 | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | June 2015 | February 2025 |
| NCT02638389 | Recruiting | Phase 3 | Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care | January 25, 2016 | April 1, 2030 |
| NCT02790515 | Recruiting | Phase 2 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | July 14, 2016 | July 1, 2025 |
| NCT02979873 | Recruiting | Phase 2 | Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy | December 19, 2016 | August 31, 2024 |
| NCT03099356 | Recruiting | Phase 2 | Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | April 27, 2017 | May 2025 |
| NCT03121001 | Recruiting | Phase 2 | Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease | March 20, 2017 | November 2025 |
| NCT03150914 | Recruiting | Phase 3 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial | January 1, 2018 | June 30, 2025 |
| NCT03214354 | Recruiting | Phase 2 | Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor | July 5, 2017 | July 2028 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT03910452 | Recruiting | Early Phase 1 | Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide | October 28, 2019 | June 15, 2034 |
| NCT03933904 | Recruiting | Phase 2 | Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | September 25, 2019 | June 30, 2025 |
| NCT03952637 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis | August 19, 2019 | January 1, 2028 |
| NCT03970096 | Recruiting | Phase 2 | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | November 19, 2019 | December 31, 2028 |
| NCT03983850 | Recruiting | Phase 1/Phase 2 | Optimizing PTCy Dose and Timing | July 9, 2019 | May 29, 2026 |
| NCT04047576 | Recruiting | Phase 2/Phase 3 | Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis | July 1, 2018 | December 2026 |
| NCT04127578 | Recruiting | Phase 1/Phase 2 | Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | January 3, 2020 | June 2029 |
| NCT04141020 | Recruiting | Phase 2 | Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms | October 27, 2021 | November 1, 2026 |
| NCT04177004 | Recruiting | Phase 1 | Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | April 30, 2021 | December 31, 2024 |
| NCT04469530 | Recruiting | Phase 2 | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors | September 16, 2020 | September 2025 |
| NCT04582136 | Recruiting | Phase 2 | Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus | March 4, 2021 | May 1, 2025 |
| NCT04789070 | Recruiting | Phase 3 | Phase III Trial of Sirolimus in IBM | July 1, 2022 | February 1, 2024 |
| NCT04861064 | Recruiting | Phase 2 | Weekly Sirolimus Therapy | January 18, 2022 | June 2025 |
| NCT04888741 | Recruiting | Phase 2 | Methods of T Cell Depletion Trial (MoTD) | February 22, 2021 | January 2026 |
| NCT04948203 | Recruiting | Phase 2/Phase 3 | Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | July 9, 2021 | June 2024 |
| NCT04959175 | Recruiting | Phase 1/Phase 2 | Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | September 23, 2021 | April 30, 2027 |
| NCT05104983 | Recruiting | Phase 2 | Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | October 13, 2021 | June 30, 2026 |
| NCT05237687 | Recruiting | Phase 2 | The Role of Sirolimus in Preventing Functional Decline in Older Adults | July 2024 | November 2025 |
| NCT05269849 | Recruiting | Phase 2 | Sirolimus for Nosebleeds in HHT | March 16, 2022 | February 10, 2025 |
| NCT05324384 | Recruiting | Phase 2 | Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma | April 5, 2022 | November 30, 2025 |
| NCT05327023 | Recruiting | Phase 1/Phase 2 | Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | May 23, 2022 | July 2, 2029 |
| NCT05357482 | Recruiting | Phase 1/Phase 2 | Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia | May 12, 2022 | November 1, 2033 |
| NCT05384756 | Recruiting | Phase 1 | TMLI and Alemtuzumab for Treatment of Sickle Cell Disease | July 13, 2022 | December 1, 2026 |
| NCT05386914 | Recruiting | Phase 1 | Short Term Sirolimus Treatment and MRI of the Brain | March 2, 2023 | December 2024 |
| NCT05425056 | Recruiting | Phase 3 | A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery | August 26, 2022 | September 2024 |
| NCT05426252 | Recruiting | Phase 1/Phase 2 | Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia | March 22, 2022 | December 31, 2026 |
| NCT05436418 | Recruiting | Phase 1/Phase 2 | The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | November 18, 2022 | July 2, 2027 |
| NCT05463133 | Recruiting | Phase 1/Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists | July 8, 2022 | December 31, 2032 |
| NCT05549167 | Recruiting | Phase 3 | Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA) | May 30, 2022 | December 30, 2029 |
| NCT05896839 | Recruiting | Phase 1/Phase 2 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | August 11, 2024 | January 31, 2027 |
| NCT05925023 | Recruiting | Phase 2 | Sirolimus in the Treatment of Refractory/Relapsed wAIHA | June 24, 2023 | December 2025 |
| NCT05949658 | Recruiting | Phase 1 | Rapalog Pharmacology (RAP PAC) Study | May 15, 2024 | December 2028 |
| NCT06055608 | Recruiting | Phase 2 | Advancing Transplantation Outcomes in Children | May 22, 2024 | November 1, 2028 |
| NCT06236022 | Recruiting | Phase 4 | The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus | January 1, 2024 | December 31, 2028 |
| NCT04083183 | Suspended | Phase 1/Phase 2 | Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases | June 16, 2020 | January 9, 2028 |
| NCT05027945 | Suspended | Phase 2 | A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome | February 23, 2023 | July 1, 2026 |
| NCT01116232 | Terminated | Phase 2 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation | August 2010 | June 2013 |
| NCT00023244 | Terminated | Phase 2 | Steroid Withdrawal in Pediatric Kidney Transplant Recipients | January 2001 | June 2005 |
| NCT01166724 | Terminated | Phase 3 | Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- | July 2010 | December 2014 |
| NCT00923273 | Terminated | Phase 1/Phase 2 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | February 29, 2008 | March 10, 2013 |
| NCT00866684 | Terminated | Phase 4 | Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol | January 2007 | July 2011 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00005113 | Terminated | Phase 3 | A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant | July 1999 | March 2006 |
| NCT00137345 | Terminated | Phase 3 | Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients | June 2005 | August 2006 |
| NCT00712491 | Terminated | Phase 1/Phase 2 | Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration | September 2008 | March 2010 |
| NCT00240214 | Terminated | Study Evaluating Rapamune in Patients After Kidney Transplantation | April 2001 | February 2008 | |
| NCT00095329 | Terminated | Phase 1/Phase 2 | Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor | May 2003 | March 2005 |
| NCT00672204 | Terminated | Phase 1/Phase 2 | Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes | November 2007 | August 2012 |
| NCT00548717 | Terminated | Phase 2 | Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation | October 2007 | September 2013 |
| NCT04348292 | Terminated | Phase 1 | Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer | January 22, 2021 | November 4, 2022 |
| NCT00506948 | Terminated | Phase 2 | Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) | September 2006 | October 2010 |
| NCT00166712 | Terminated | Phase 4 | A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression | April 2005 | April 2010 |
| NCT00489281 | Terminated | Phase 2 | Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders | June 23, 2008 | December 29, 2018 |
| NCT00473551 | Terminated | Phase 1 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | May 2007 | November 2009 |
| NCT02282904 | Terminated | Phase 1/Phase 2 | Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide | October 23, 2014 | December 10, 2019 |
| NCT02214706 | Terminated | N/A | Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus | July 2014 | December 2016 |
| NCT02565901 | Terminated | Phase 1/Phase 2 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | February 29, 2016 | June 16, 2020 |
| NCT00311311 | Terminated | Phase 3 | Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients | April 2006 | January 2012 |
| NCT02123966 | Terminated | Phase 2 | An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease | July 2014 | May 2016 |
| NCT02110069 | Terminated | Phase 2 | A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors | June 14, 2017 | October 27, 2020 |
| NCT00468442 | Terminated | Phase 2 | B-Lymphocyte Immunotherapy in Islet Transplantation | November 2006 | September 2011 |
| NCT02678143 | Terminated | Phase 1 | Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease | April 26, 2016 | November 16, 2021 |
| NCT02013375 | Terminated | Phase 2 | SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD | April 10, 2014 | September 7, 2018 |
| NCT01962896 | Terminated | Phase 2 | A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors | January 8, 2014 | January 27, 2018 |
| NCT01814059 | Terminated | Phase 1 | Sirolimus for Eosinophil-Associated Gastrointestinal Disorders | March 7, 2013 | May 12, 2015 |
| NCT01797315 | Terminated | Phase 4 | Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol | March 2007 | June 2013 |
| NCT02728700 | Terminated | Phase 1 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | February 2016 | July 2018 |
| NCT01764607 | Terminated | Phase 2 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | April 2013 | June 2014 |
| NCT01709136 | Terminated | Phase 2/Phase 3 | Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity | December 2005 | January 2010 |
| NCT01675947 | Terminated | Phase 2 | Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy | February 2012 | February 2016 |
| NCT00358657 | Terminated | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders | May 24, 2006 | May 25, 2019 |
| NCT01658007 | Terminated | Early Phase 1 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma | August 2012 | January 2017 |
| NCT01534143 | Terminated | Phase 2 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | February 2012 | May 2013 |
| NCT01488253 | Terminated | Phase 2 | Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants | January 2012 | October 2014 |
| NCT00346151 | Terminated | Phase 2 | Belatacept to Prevent Organ Rejection in Kidney Transplant Patients | December 2006 | February 2010 |
| NCT01318915 | Terminated | Early Phase 1 | Research Study of ATG and Rituximab in Renal Transplantation | July 25, 2011 | August 25, 2017 |
| NCT01303965 | Terminated | Phase 1/Phase 2 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | February 7, 2011 | July 28, 2017 |
| NCT00068302 | Terminated | Phase 1 | Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma | January 2003 | July 2013 |
| NCT01223755 | Terminated | Phase 2/Phase 3 | Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency | September 2010 | July 2012 |
| NCT01220297 | Terminated | Phase 2 | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | August 2006 | August 2011 |
| NCT03421756 | Terminated | Early Phase 1 | Stem Cell Transplant in Patients With Severe Sickle Cell Disease | March 29, 2018 | May 15, 2022 |
| NCT00934791 | Terminated | N/A | Polycystic Liver Disease in Kidney Transplant | February 2009 | December 2012 |
| NCT00931255 | Terminated | Phase 4 | Tacrolimus to Sirolimus Conversion for Delayed Graft Function | April 2009 | July 2014 |
| NCT02055079 | Unknown status | Phase 3 | Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease | April 2014 | December 2019 |
| NCT03688191 | Unknown status | Phase 4 | Study of Sirolimus in CTD-TP in China | September 21, 2017 | September 30, 2019 |
| NCT03866681 | Unknown status | Phase 4 | Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH | April 1, 2019 | April 1, 2022 |
| NCT00141804 | Unknown status | Phase 3 | Efficacy and Safety of Sirolimus in Combination With Tacrolimus | January 2002 | June 2005 |
| NCT03942926 | Unknown status | Phase 2 | The Efficacy and Safety of Sirolimus for Plastic Bronchitis | May 6, 2019 | May 5, 2020 |
| NCT01034345 | Unknown status | Phase 2 | Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients | November 2009 | November 2011 |
| NCT03987152 | Unknown status | Phase 3 | Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life | September 18, 2017 | March 1, 2023 |
| NCT05193565 | Unknown status | Phase 4 | Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients | November 19, 2021 | June 2024 |
| NCT04892212 | Unknown status | Phase 2/Phase 3 | Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis | June 30, 2021 | October 30, 2023 |
| NCT00319878 | Unknown status | Phase 1/Phase 2 | Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia | May 2006 | December 2009 |
| NCT00693446 | Unknown status | Phase 4 | A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids | April 2004 | April 2017 |
| NCT00554125 | Unknown status | Phase 3 | Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria | August 2007 | August 2013 |
| NCT01680250 | Unknown status | Phase 2/Phase 3 | Sirolimus for Massive Polycystic Liver | September 2011 | August 2015 |
| NCT00493194 | Unknown status | Phase 4 | Fibrosis in Renal Allografts | May 2005 | July 2007 |
| NCT00490789 | Unknown status | Phase 2 | Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | October 2005 | September 2009 |
| NCT04461340 | Unknown status | Phase 2 | Efficacy and Safety of Sirolimus in COVID-19 Infection | August 15, 2020 | November 30, 2020 |
| NCT01446484 | Unknown status | Phase 1/Phase 2 | Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection | October 2011 | November 2014 |
| NCT00999258 | Unknown status | Phase 4 | Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients | September 2009 | June 2011 |
| NCT03365869 | Unknown status | Phase 2 | A Pilot-Study of Sirolimus for the Treatment of Systemic Sclerosis | June 1, 2018 | June 30, 2019 |
| NCT00975819 | Unknown status | Phase 2 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | October 2009 | October 2019 |
| NCT03500848 | Unknown status | Phase 2/Phase 3 | Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation | May 1, 2018 | May 31, 2023 |
| NCT01592253 | Unknown status | N/A | Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient | May 2012 | December 2013 |
| NCT02208791 | Unknown status | Phase 4 | Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant | July 2014 | July 2017 |
| NCT03662412 | Unknown status | Phase 1/Phase 2 | Study of Sirolimus in Patients With Advanced Pancreatic Cancer | June 1, 2018 | June 30, 2023 |
| NCT00995059 | Withdrawn | Phase 1/Phase 2 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | ||
| NCT02524639 | Withdrawn | Phase 1/Phase 2 | Sirolimus for the Treatment of Hyperinsulinism | August 12, 2015 | May 29, 2018 |
| NCT00002790 | Withdrawn | Phase 1/Phase 2 | Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant | March 1996 | |
| NCT02833506 | Withdrawn | Phase 1 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | December 8, 2017 | August 15, 2019 |
| NCT00957320 | Withdrawn | Phase 1 | Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) | June 2009 | August 2012 |
| NCT02365415 | Withdrawn | Phase 2 | Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement | February 2015 | April 2018 |
| NCT00098462 | Withdrawn | Phase 1/Phase 2 | Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer | October 2004 | |
| NCT01383668 | Withdrawn | Phase 1 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | June 2011 | February 8, 2013 |
| NCT03531281 | Withdrawn | Phase 1 | Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | December 30, 2018 | December 30, 2022 |
| NCT02528877 | Withdrawn | Phase 1 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | November 2015 | |
| NCT05170828 | Withdrawn | Phase 1 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | September 2022 | November 2024 |
| NCT01305395 | Withdrawn | N/A | Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients | November 2010 | January 2015 |
| NCT02126527 | Withdrawn | Phase 1 | Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer | August 2013 | |
| NCT00790439 | Withdrawn | Phase 2 | Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant | July 2008 | October 2009 |
| NCT01492894 | Withdrawn | Phase 4 | Kidney Allograft Dysfunction Without Reversible Causes | January 2008 | October 2011 |
| NCT02177760 | Withdrawn | Phase 2 | Sirolimus Prophylaxis for aGVHD in TME SCID | July 2014 | November 2015 |
| NCT02062892 | Withdrawn | Phase 4 | Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients | December 2013 | June 2014 |